drugset
Drugs / INT301
last change Jan 2025 re-read 3 minutes ago

INT301

Protein / enzyme biologic

Developed for
food allergy

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 1 NCT04603300 Comparator May 2021 → Jun 2023 food allergy Intrommune Therapeutics Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2023-11-09 Intrommune Therapeutics Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy intrommune.com ↗
2021-02-04 Intrommune Therapeutics Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301 intrommune.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as INT301 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04603300 ↗
Modality Protein / enzyme biologic “OMIT involves the use of a specifically formulated toothpaste to deliver allergenic proteins to immunologically active areas of the oral cavity.” PMID 39842774 ↗ Jan 2025
Route Oral “Oral mucosal immunotherapy (OMIT) involves the use of a specifically formulated toothpaste to deliver allergenic proteins to immunologically active areas of the oral cavity.” PMID 39842774 ↗ Jan 2025